Market Place
Sourcing Support
Nicox Provides Q3 2024 Update And First Half 2024 Financial Results
17 Oct 2024 //
GLOBENEWSWIRE
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
14 Oct 2024 //
GLOBENEWSWIRE
Nicox Announces Approval of ZERVIATE in China
18 Sep 2024 //
GLOBENEWSWIRE
Nicox Appoints Christine Placet To Board Of Directors
04 Sep 2024 //
GLOBENEWSWIRE
Nicox Completes US Patient Recruitment For NCX 470 Phase 3 Trial
24 Jul 2024 //
GLOBENEWSWIRE
Nicox Provides Second Quarter 2024 Update
18 Jul 2024 //
GLOBENEWSWIRE
Nicox Appoints New Board Chair And Director
16 Jul 2024 //
GLOBENEWSWIRE
Nicox: 2024 Ordinary Shareholder Meeting
27 Jun 2024 //
GLOBENEWSWIRE
Number of voting rights as of May 31, 2024
03 Jun 2024 //
GLOBENEWSWIRE
Nicox`s Ordinary and Extraordinary Shareholders` Meeting on May 6, 2024
06 May 2024 //
GLOBENEWSWIRE
Number of voting rights as of April 30, 2024
02 May 2024 //
GLOBENEWSWIRE
Nicox: Shareholders Meeting Notice, Ad Hoc Agent Appointed
24 Apr 2024 //
GLOBENEWSWIRE
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
22 Apr 2024 //
GLOBENEWSWIRE
Nicox`s Shareholder Letter
22 Mar 2024 //
GLOBENEWSWIRE
Nicox Updates on Corporate, Pipeline and Financing Perspectives
13 Mar 2024 //
GLOBENEWSWIRE
Nicox Announces Presentation of Data on NCX 470
05 Mar 2024 //
GLOBENEWSWIRE
Number of voting rights as of February 29, 2024
01 Mar 2024 //
GLOBENEWSWIRE
With cash runways ending, Nicox and Longeveron plan layoffs
28 Feb 2024 //
FIERCE BIOTECH
Nicox Restructures Debt
27 Feb 2024 //
GLOBENEWSWIRE
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
27 Feb 2024 //
GLOBENEWSWIRE
Nicox and Kowa Enter into Agreement for NCX 470
08 Feb 2024 //
GLOBENEWSWIRE
Nicox announces presentations at the upcoming Association for Research
06 Feb 2024 //
GLOBENEWSWIRE
Nicox Receives Confirmation of 5-year Patent Term Extension for VYZULTA
31 Jan 2024 //
GLOBENEWSWIRE
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
25 Jan 2024 //
GLOBENEWSWIRE
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux
08 Jan 2024 //
GLOBENEWSWIRE
Nicox : Termination of the liquidity contract with Kepler Cheuvreux
03 Jan 2024 //
GLOBENEWSWIRE
Number of voting rights as of December 31, 2023
02 Jan 2024 //
GLOBENEWSWIRE
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470
18 Dec 2023 //
GLOBENEWSWIRE
Nicox™s Announces Publication of New Nonclinical Data
14 Dec 2023 //
GLOBENEWSWIRE
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results
20 Oct 2023 //
GLOBENEWSWIRE
Monthly Publication Of The Number Of Shares Composing The Share Capital
02 Oct 2023 //
GLOBENEWSWIRE
Monthly Publication of the Number of Shares Composing the Share Capital
01 Sep 2023 //
GLOBENEWSWIRE
Monthly Publication of the Number of Shares Composing the Share Capital
01 Aug 2023 //
GLOBENEWSWIRE
Nicox announces attendance at upcoming conferences
19 Jul 2023 //
GLOBENEWSWIRE
Nicox Provides Second Quarter 2023 Financial and Business Highlights
19 Jul 2023 //
GLOBENEWSWIRE
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
11 Jul 2023 //
GLOBENEWSWIRE
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of $300 million
10 Jul 2023 //
GLOBENEWSWIRE
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data
03 Jul 2023 //
GLOBENEWSWIRE
Monthly Publication of The Number Of Shares Composing The Share Capital
03 Jul 2023 //
GLOBENEWSWIRE
Nicox: 2023 Ordinary Shareholder Meeting
02 Jun 2023 //
GLOBENEWSWIRE
Monthly Publication of the Number of Shares Composing the Share Capital
01 Jun 2023 //
GLOBENEWSWIRE
Nicox`s Partner Ocumension Receives Priority Review for ZERVIATE NDA in China
28 Apr 2023 //
GLOBENEWSWIRE
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Number of voting rigts as of April 24, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Publication of Number of Shares Composing the Share Capital as of March 31, 2023
03 Apr 2023 //
GLOBENEWSWIRE
Nicox Announces Presentations of Additional NCX 470 Data at Glaucoma Congress
21 Mar 2023 //
GLOBENEWSWIRE
Nicox Reports 2022 Financial Results and Updates Key Future Milestones
20 Mar 2023 //
GLOBENEWSWIRE
Nicox to Present at Upcoming Scientific Conferences
03 Mar 2023 //
GLOBENEWSWIRE
Nicox`s Ordinary Shareholder Meeting to be held on February 28, 2023
13 Feb 2023 //
GLOBENEWSWIRE
Number of voting rights as of January 31, 2023
01 Feb 2023 //
GLOBENEWSWIRE
Nicox to Participate in Financial, Pharmaceutical Industry Events in H1 2023
24 Jan 2023 //
GLOBENEWSWIRE
Nicox Provides Fourth Quarter 2022 Financial Highlights
18 Jan 2023 //
GLOBENEWSWIRE
Nicox Announces Proposed Move to Euronext Growth Paris
09 Jan 2023 //
GLOBENEWSWIRE
Nicox Raises €10 Million in Private Placemen
21 Nov 2022 //
GLOBENEWSWIRE
Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma
07 Nov 2022 //
GLOBENEWSWIRE
Nicox Reports Achieving Primary Objective in Mont Blanc
31 Oct 2022 //
GLOBENEWSWIRE
Nicox Provides Third Quarter 2022 Financial and Business Highlights
19 Oct 2022 //
GLOBENEWSWIRE
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3
19 Sep 2022 //
GLOBENEWSWIRE
Nicox Provides First Half 2022 Business Update and Financial Results
15 Sep 2022 //
GLOBENEWSWIRE
Nicox to Participate in Financial and Scientific Events in Q3 2022
03 Aug 2022 //
GLOBENEWSWIRE
